Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Harrison

Showing results (191-200 of 270) with videos related to

Pageof 27
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2024
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 StudyStephen A Harrison, Juan P Frias, K Jean Lucas, et al.
Biomedicines|December 24, 2021
Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver DiseaseAnne Linde Mak, Jenny Lee, Anne-Marieke van Dijk, et al.
Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Hepatology Communications|May 9, 2022
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018Emily Truong, Yee Hui Yeo, Galen Cook-Wiens, et al.
The New England Journal of Medicine|December 1, 2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitisRenata Belfort, Stephen A Harrison, Kenneth Brown, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver ForumMelissa Palmer, David E Kleiner, Zachary Goodman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 20, 2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Quentin M Anstee, et al.
Gastroenterology|December 9, 2019
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionNaga Chalasani, Manal F Abdelmalek, Guadalupe Garcia-Tsao, et al.
Gastroenterology|October 4, 2021
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver DiseaseFasiha Kanwal, Jay H Shubrook, Leon A Adams, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceMohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Pageof 27

Showing results (191-200 of 270) with videos related to

Sort By:
Pageof 27
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2024
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 StudyStephen A Harrison, Juan P Frias, K Jean Lucas, et al.
Biomedicines|December 24, 2021
Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver DiseaseAnne Linde Mak, Jenny Lee, Anne-Marieke van Dijk, et al.
Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Hepatology Communications|May 9, 2022
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018Emily Truong, Yee Hui Yeo, Galen Cook-Wiens, et al.
The New England Journal of Medicine|December 1, 2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitisRenata Belfort, Stephen A Harrison, Kenneth Brown, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver ForumMelissa Palmer, David E Kleiner, Zachary Goodman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 20, 2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Quentin M Anstee, et al.
Gastroenterology|December 9, 2019
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionNaga Chalasani, Manal F Abdelmalek, Guadalupe Garcia-Tsao, et al.
Gastroenterology|October 4, 2021
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver DiseaseFasiha Kanwal, Jay H Shubrook, Leon A Adams, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceMohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Pageof 27